 Home > Active Ingredient News > Antitumor Therapy > JAMA Oncol: A new adjuvant therapy for locally advanced colorectal cancer-radiotherapy and chemotherapy + induction/consolidation chemotherapy!

JAMA Oncol: A new adjuvant therapy for locally advanced colorectal cancer-radiotherapy and chemotherapy + induction/consolidation chemotherapy!

 Last Update: 2021-12-25
 Source: Internet
 Author: User

Tags

warcef trial

lumin skin free trial

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Now, multi-modeIncreasingly, new adjuvant treatments are used in the treatment of colorectal cancer

Colorectal cancer

The CAO/ARO/AIO-12 study is a randomized phase 2 clinical trial that studies the comparison of the effects of radiotherapy and chemotherapy combined with induction or consolidation chemotherapy as a neoadjuvant treatment

From June 15, 2015 to January 31, 2018, a total of 311 patients with cT3-4 stage and/or lymph node positive colorectal adenocarcinoma were recruited from 18 medical centers in Germany

Disease-free survival of the two groups

Among the 311 subjects, 306 can be included in this assessment, including 156 in group A (average 60 years old, 68% men) and 150 in group B (average 62 years old, 67% men)

After a median follow-up of 43 months, the 3-year disease-free survival rate of both groups was 73% .

Distant metastasis rate of the two groups

In 3 years, 10 out of 85 patients in group A (11.

In summary, the secondary analysis of this randomized trial showed that chemotherapy after CRT can increase the pathological complete remission rate of patients with advanced colorectal cancer without affecting disease-free survival, toxicity, and QoL

Chemotherapy after CRT can increase the pathological complete remission rate of patients with advanced colorectal cancer, and does not affect disease-free survival, toxicity, and QoL Chemotherapy after CRT can increase the pathological complete remission rate of patients with advanced colorectal cancer without affecting disease-free Survival time, toxicity, QoL

Original source:

Fokas E, Schlenska-Lange A, Polat B, et al.

Induction or Consolidation Chemotherapy Plus Chemoradiotherapy AS Neoadjuvant the Total Therapy for Patients With Locally Advanced Rectal Cancer: Results of Long-Term The CAO / ARO / 12 is the AIO-Randomized Clinical Trial JAMA

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.